Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05654883 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05654883 · ClinicalTrials.gov record · last posted 2026-08-27

New York City Observational Study of Mpox Immunity

Study acronym: NYC OSMI
StatusEnrolling by Invitation
PhaseNot specified
Started2022-11-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.

Protocol amendment history 2 changes detected by DataLookout

2026-08-28
Primary completion pushed: 2023-09-11 → 2027-07-06
2026-08-28
Completion pushed: 2026-06 → 2027-07-06
Trial Details
NCT Number NCT05654883
Lead Sponsor NYU Langone Health
Conditions Monkeypox, Mpox, HIV
Enrollment 188 participants
Start Date 2022-11-11
Primary Completion 2027-07-06 (estimated)
Study Completion 2027-07-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-27